05 November 2021
By Maynard Paton
Results summary for Bioventix (BVXP):
- Acceptable annual figures that included a record H2 profit (+14%) despite the pandemic continuing to disrupt demand for routine blood tests.
- Mixed progress from vitamin D and other established antibodies leaves near-term growth dependent mostly on the fast-selling troponin product.
- Additional research efforts suggest pyrene biomonitoring and detecting Alzheimer’s disease may be the more likely long-term pipeline winners.
- A 19% dividend lift, another special payout, 70%-plus margins and low retained-profit requirements underlined the wonderful economics of collecting antibody royalties.
- Troponin’s finite income and a resultant sum-of-the-parts valuation do not indicate an obviously tantalising £36 share price. I continue to hold.





